Skip to main content
Fig. 3 | BMC Endocrine Disorders

Fig. 3

From: Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)

Fig. 3

IGF-1 SDS values for lanreotide autogel and lanreotide 40 mg PR. a) Treatment differences for LS mean changes between baseline and end-of-study/early withdrawal visit (primary endpoint). b) Age-adjusted actual values during the study. Data in figure a are LS mean treatment differences (lanreotide autogel minus lanreotide 40 mg PR) [95% CI] from age-adjusted log-transformed values and based on a generalized linear model with IGF-1 SDS change as dependent variable, treatment group and previous surgery as independent factors, and baseline IGF-1 SDS value as independent covariate. Data in figure b are age-adjusted actual values. The primary efficacy analysis was based on the PP population and the supportive analysis on the ITT population. CI, confidence interval; IGF-1, insulin-like growth factor-1; ITT, intention to treat; LS, least squares; PP, per protocol; PR, prolonged release; SDS, standard deviation scores

Back to article page